CUE (Cue Biopharma) Moat Score: 3/10 (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CUE Cue Biopharma Inc CUE
45 GF Score
Price $27.64
! 6 Warning Signs
View Full Analysis

What is Cue Biopharma Moat Score?

Cue Biopharma CUE -19.17% 45 Moat Score is 3 as of Aug. 17, 2026. GuruFocus rates CUE with a GF Score™ of 45/100. The stock has 6 warning signs investors should review. Among 1,388 Biotechnology companies, Cue Biopharma ranks better than 75.5% on this metric.

Cue Biopharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Cue Biopharma has No Moat: Cue Biopharma Inc operates in the competitive biotech sector with limited market share and no significant intellectual property that stands out. The company lacks strong brand strength, customer loyalty, and durable cost advantages. Regulatory barriers exist but are not exclusive to the company.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cue Biopharma might have No Moat - Very weak/transient advantages.

Cue Biopharma  (NAS:CUE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cue Biopharma Moat Score Related Terms

CUE vs CNTB, CDXS, HURA: Moat Score Comparison

For the Biotechnology subindustry, Cue Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cue Biopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Moat Score falls into.


CUE
45GF Score
Cue Biopharma Inc CUE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Cue Biopharma (CUE) has a Moat Score of 3 as of Aug. 17, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cue Biopharma ranks #340 out of 1388 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Cue Biopharma's Moat Score too high?
Cue Biopharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Cue Biopharma's value of 3 is 50% above this industry median. Based on the distribution chart, Cue Biopharma ranks #340 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cue Biopharma has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Moat Score compare to CNTB and CDXS?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #340 out of 1388 companies for Moat Score. This places Cue Biopharma in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Cue Biopharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cue Biopharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Cue Biopharma (CUE) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Cue Biopharma's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Moat Score is 3 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
45GF Score

Get the complete analysis for CUE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.64
Price